Evaluation: Big Pharma shies away from CEPI due to equitable access requirements
NewsDecember 19, 2022
/ By: Ann Danaiya Usher
The Oslo-based vaccine initiative CEPI has over a few short years grown into a “credible and prominent” global actor but risks spreading itself too thin as it expands its mandate to include vaccine manufacturing, a recent evaluation concludes. CEPI also faces a dilemma: profit-driven Big Pharma has largely refused to engage with CEPI because of equitable access conditions attached to grants.
The rest of the content is only available for subscribers.